What is Neurogene Inc. (NGNE)?

Neurogene Inc. (NGNE) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of NGNE?

The current price of NGNE is $28.82. Prices are updated in real time on Stocks360.

What is NGNE's price-to-earnings (PE) ratio?

NGNE's trailing twelve-month PE ratio is -5.23, based on current price and earnings per share data available on Stocks360.

What is NGNE's market capitalization?

NGNE's market capitalization is $455,423,035.00, placing it in the small-cap tier.

Neurogene Inc. (NGNE)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$28.82

Market Cap

$455.42M

PE (TTM)

-5.23

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.09

Day Range

$28.50 – $32.09

52-wk Range

$15.93 – $43.66

Avg Volume

N/A

Volume

309.63K

Neurogene Inc. (NGNE) is a publicly traded company in the Healthcare sector. Latest price: $28.82. Market cap $455.42M. Trailing PE -5.23. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $33.14 2026-10-29 · $28.82 (-13.04%)

Earnings

Most Recent

Aug 11, 2026

EPS $-1.53 vs est. $-1.42

Missed by $0.11

Next Earnings

Nov 12, 2026

EPS estimate $-1.49

Proprietary Signals

Signal snapshot temporarily unavailable.

About Neurogene Inc.

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-5.23×
P/S (TTM)	0.00×
P/B	2.99×
PEG	0.30×
P/FCF (TTM)	-5.23×
EV / EBITDA	-3.26×
EV / Sales	0.00×
Earnings Yield	-17.10%
Free Cash Flow Yield	-19.13%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$351.28M
Net Income (TTM)	-$77.86M
Free Cash Flow (TTM)	-$87.11M
Net Debt	-$104.14M
Working Capital	$207.41M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-45.11%
Return on Invested Capital	-53.72%